22
Dec

Johnson & Johnson is fronting $125 million to gain the worldwide license on a bispecific cancer drug from MacroGenics, with up to $575 million more promised in prospective milestones for a successful development program. And the biotech says that the deal marks the beginning of a new program for a drug designed to stir a T cell attack against blood cancers.

…read more

Source: UPDATED: J&J steps up with $700M deal for MacroGenics’ blood cancer drug, shares spike

    

0 No comments